There is limited data on optimal treatment of advanced non-clear cell RCC in general, including unclassified RCC. I have summarized the available data that I am aware of: The phase II study ASPEN randomized advanced nccRCC patients, including 20% with unclassified RCC, to sunitinib vs everolimus. Of...